消化

订阅

MedSci主页 / 所有栏目 / 消化

JCC: IL-6缺失会加剧IL-10缺乏小鼠的结肠炎并诱发全身性炎症反应

2020-07-12 MedSci原创 MedSci原创

IL-6结肠炎IL-10
关注

白介素6 [IL-6]或其受体目前是炎症性肠病[IBD]靶向生物治疗的候选目标。

背景和目标

白介素6 [IL-6]或其受体目前是炎症性肠病[IBD]靶向生物治疗的候选目标。因此，必须全面了解阻断IL-6的效果。本项研究旨在通过评估IL-6缺失对IL-10-缺陷小鼠[IL-10 -/- ] 自发性结肠炎的影响进行了探究。

 

方法

研究人员将产生IL-6 / IL-10双缺陷[IL-6 -/- / IL-10 -/- ]小鼠与野生型相比结肠粘膜的肠道炎症。

 

结果

出乎意料的是，IL-6 -/- / IL-10 -/-小鼠表现出比IL-10 -/-小鼠更明显的肠道炎症和更早的疾病发作，无论是局部[结肠和小肠]还是全身性[脾肿大，溃疡性皮炎] ，白细胞增多，中性粒细胞增多和单核细胞增多]。IL-6 -/- / IL-10 -/-小鼠表现出多种细胞因子[IL-1β，IL-4，IL-12，TNFα]和趋化因子[MCP-1和MIG]的升高，但IFN-γ没有升高。

 

结论

在IL-10 -/-小鼠可以部分通过抑制Treg / CTLA-4并促进IL-1β/ Th2途径，完全IL-6阻断可显着加重肠道炎症。另外，双重突变体表现出严重的全身性炎症的迹象。

 

原始出处：

Mei Ye. Et al. Deletion of IL-6 Exacerbates Colitis and Induces Systemic Inflammation in IL-10-Deficient Mice. Journal of Crohn's and Colitis. 2020.

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1273793, encodeId=df1e12e3793bf, content=<a href='/topic/show?id=fae896e7ea' target=_blank style='color:#2F92EE;'>#IL-6#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9677, encryptionId=fae896e7ea, topicName=IL-6)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Tue Jul 14 02:46:08 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1320895, encodeId=75041320895d6, content=<a href='/topic/show?id=43de6e0076f' target=_blank style='color:#2F92EE;'>#炎症反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67007, encryptionId=43de6e0076f, topicName=炎症反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b73f484, createdName=lsj628, createdTime=Tue Jul 14 02:46:08 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508288, encodeId=c6921508288f3, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Tue Jul 14 02:46:08 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587652, encodeId=cac2158e6525c, content=<a href='/topic/show?id=a6f6962576' target=_blank style='color:#2F92EE;'>#IL-10#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9625, encryptionId=a6f6962576, topicName=IL-10)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Jul 14 02:46:08 CST 2020, time=2020-07-14, status=1, ipAttribution=)]
    2020-07-14 kzlchina

    #IL-6#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1273793, encodeId=df1e12e3793bf, content=<a href='/topic/show?id=fae896e7ea' target=_blank style='color:#2F92EE;'>#IL-6#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9677, encryptionId=fae896e7ea, topicName=IL-6)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Tue Jul 14 02:46:08 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1320895, encodeId=75041320895d6, content=<a href='/topic/show?id=43de6e0076f' target=_blank style='color:#2F92EE;'>#炎症反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67007, encryptionId=43de6e0076f, topicName=炎症反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b73f484, createdName=lsj628, createdTime=Tue Jul 14 02:46:08 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508288, encodeId=c6921508288f3, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Tue Jul 14 02:46:08 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587652, encodeId=cac2158e6525c, content=<a href='/topic/show?id=a6f6962576' target=_blank style='color:#2F92EE;'>#IL-10#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9625, encryptionId=a6f6962576, topicName=IL-10)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Jul 14 02:46:08 CST 2020, time=2020-07-14, status=1, ipAttribution=)]
    2020-07-14 lsj628

    #炎症反应#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1273793, encodeId=df1e12e3793bf, content=<a href='/topic/show?id=fae896e7ea' target=_blank style='color:#2F92EE;'>#IL-6#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9677, encryptionId=fae896e7ea, topicName=IL-6)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Tue Jul 14 02:46:08 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1320895, encodeId=75041320895d6, content=<a href='/topic/show?id=43de6e0076f' target=_blank style='color:#2F92EE;'>#炎症反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67007, encryptionId=43de6e0076f, topicName=炎症反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b73f484, createdName=lsj628, createdTime=Tue Jul 14 02:46:08 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508288, encodeId=c6921508288f3, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Tue Jul 14 02:46:08 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587652, encodeId=cac2158e6525c, content=<a href='/topic/show?id=a6f6962576' target=_blank style='color:#2F92EE;'>#IL-10#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9625, encryptionId=a6f6962576, topicName=IL-10)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Jul 14 02:46:08 CST 2020, time=2020-07-14, status=1, ipAttribution=)]
    2020-07-14 jjjiang0202

    #IL-1#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1273793, encodeId=df1e12e3793bf, content=<a href='/topic/show?id=fae896e7ea' target=_blank style='color:#2F92EE;'>#IL-6#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9677, encryptionId=fae896e7ea, topicName=IL-6)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Tue Jul 14 02:46:08 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1320895, encodeId=75041320895d6, content=<a href='/topic/show?id=43de6e0076f' target=_blank style='color:#2F92EE;'>#炎症反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67007, encryptionId=43de6e0076f, topicName=炎症反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b73f484, createdName=lsj628, createdTime=Tue Jul 14 02:46:08 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508288, encodeId=c6921508288f3, content=<a href='/topic/show?id=8d4596248e' target=_blank style='color:#2F92EE;'>#IL-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9624, encryptionId=8d4596248e, topicName=IL-1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6cf9946833, createdName=jjjiang0202, createdTime=Tue Jul 14 02:46:08 CST 2020, time=2020-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587652, encodeId=cac2158e6525c, content=<a href='/topic/show?id=a6f6962576' target=_blank style='color:#2F92EE;'>#IL-10#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9625, encryptionId=a6f6962576, topicName=IL-10)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Jul 14 02:46:08 CST 2020, time=2020-07-14, status=1, ipAttribution=)]
    2020-07-14 柳叶一刀

    #IL-10#

    0

相关资讯

Blood：特发性多中心Castleman病的mTOR激活增强

在特发性多中心Castleman病（iMCD）中，mTOR通路被过度激活，并被作为候选新型治疗靶点。 mTOR在iMCD中的激活程度与mTOR驱动的自身免疫性淋巴组织增生综合征的相似。

Blood：树突细胞来源的IL-6失调介导alloSCT后移植物抗宿主病的发生

中心点：DCs是异体移植后IL-6失调的主要来源。IL-6依赖性GVHD受供体T细胞上的IL-6R经典信号驱动，但受反式信号调控。摘要：异体干细胞移植(alloSCT)后移植物抗宿主病(GVHD)的特点是白细胞介素-6 (IL-6)调节异常。IL-6可以通过多种途径介导作用，包括经典、反式和簇信号。鉴于近年来有多种药物可以抑制这些离散的信号级联，了解细胞因子的来源、信号和细胞靶点对临床研究的设计至

Circulation：IL-6信号遗传缺陷可可降低克隆造血变异个体的心血管风险

不确定潜能克隆性造血(Clonal hematopoiesis of indeterminate potential，CHIP)是指造血干细胞克隆扩增导致产生获得性白血病突变，如DNMT3A或TET2。在人类中，CHIP与心肌梗死相关。在小鼠中，CHIP可恶化动脉粥样硬化，增加IL-6/IL-1β的表达，引发这样一个推测：IL-6通路拮抗剂或可降低CHIP携带者的心血管疾病（CVD）风险。研究人员

Cell Death Dis：肿瘤相关成纤维细胞可影响结肠癌细胞的生理节律

生物钟可以调节蛋白质的表达水平及其功能特性，如细胞生长相关的节律，而这些作用能够调节细胞稳态和组织的整体活性。

Circulation：Regnase-1通过介导细胞因子mRNA降解抑制衰竭心脏的无菌性炎症

促炎细胞因子在心力衰竭的发病机制中起着重要作用。衰竭心脏内维持无菌性炎症的机制仍不明确。虽然转录调控对促炎细胞因子基因表达很重要，但mRNA的稳定性也有助于免疫反应的动态。Regnase-1是一种RNase，参与免疫细胞中一系列促炎细胞因子mRNA的降解。但Regnase-1在非免疫细胞(如心肌细胞)中的作用仍有待阐明。为了研究Regnase-1在心肌细胞中介导促炎细胞因子降解的作用，研究人员建立

抗类风湿性关节炎药物Kevzara治疗COVID-19：II/III期临床试验即将开展

美国卫生与公共服务部防备与响应办公室（ASPR）将支持Regeneron制药公司开展COVID-19临床试验，以评估Kevzara治疗重症COVID-19患者的有效性和安全性。